LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

40.52 2.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

40.17

Max

40.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	12.278 77.671
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+13.55% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	554M 2.2B
Ankstesnė atidarymo kaina	37.65
Ankstesnė uždarymo kaina	40.52

Naujienos nuotaikos

By Acuity

34%

66%

71 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-13 00:04; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

2025-12-12 16:42; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025-12-13 16:48; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 08:00; UTC

Įsigijimai, susijungimai, perėmimai

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

2025-12-13 00:24; UTC

Įsigijimai, susijungimai, perėmimai

Want a Piece Of SpaceX? -- Barrons.com

2025-12-12 23:49; UTC

Įsigijimai, susijungimai, perėmimai

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025-12-12 22:52; UTC

Rinkos pokalbiai

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025-12-12 22:32; UTC

Uždarbis

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025-12-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 20:45; UTC

Uždarbis

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025-12-12 20:41; UTC

Rinkos pokalbiai

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025-12-12 20:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025-12-12 19:23; UTC

Uždarbis

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025-12-12 18:35; UTC

Įsigijimai, susijungimai, perėmimai

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025-12-12 18:33; UTC

Įsigijimai, susijungimai, perėmimai

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025-12-12 18:31; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025-12-12 17:49; UTC

Uždarbis

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025-12-12 17:34; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025-12-12 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025-12-12 17:32; UTC

Įsigijimai, susijungimai, perėmimai

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025-12-12 17:31; UTC

Įsigijimai, susijungimai, perėmimai

Orange to Buy the Stake for EU4.25B in Cash

2025-12-12 17:24; UTC

Rinkos pokalbiai

Argentina Predicts Record Wheat Crop -- Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-12 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-12 17:18; UTC

Rinkos pokalbiai

Uždarbis

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025-12-12 17:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-12 16:47; UTC

Rinkos pokalbiai

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

2025-12-12 16:39; UTC

Rinkos pokalbiai

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

13.55% į viršų

12 mėnesių prognozė

Vidutinis 46 USD 13.55%

Aukščiausias 62 USD

Žemiausias 32 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

71 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.